Wiley期刊
期刊
会议
图书
作者:... Hongqi Liu , Wei Wang , Youxin Wang
来源:[J].Journal of Cellular and Molecular Medicine(IF 4.753), 2020, Vol.24 (2), pp.1837-1847Wiley
摘要:Abstract(#br)Suboptimal health status (SHS), a physical state between health and disease, is a subclinical and reversible stage of chronic disease. Previous studies have shown alterations in the intestinal microbiota in patients with some chronic diseases. This study aimed t...
作者:Wei Wang , Yang Wang ...
来源:[J].Journal of Cellular and Molecular Medicine(IF 4.753), 2019, Vol.23 (1), pp.586-595Wiley
摘要:Abstract(#br)Hepatocellular carcinoma ( HCC ) is a high incidence and mortality malignant tumour globally. Betulinic acid ( BA ) is a pentacyclic triterpenoid with potential pro‐apoptotic activities which widely found in many plants. In this study, we determined the effects ...
作者:Wei Wang , Ruiling Dong ...
来源:[J].Journal of Cellular and Molecular Medicine(IF 4.753), 2019, Vol.23 (8), pp.5486-5496Wiley
摘要:Abstract(#br)Circular RNAs (circRNAs), often dysregulated in a variety of human diseases, participate in the initiation and development of cancers. Recently, circMTO1 (a circRNA derived from MTO1 gene), identified as a tumor suppressor, has been shown to contribute to the su...
作者:Wei Wang , Hong Chang ...
来源:[J].Journal of Cellular and Molecular Medicine(IF 4.753), 2019, Vol.23 (11), pp.7331-7341Wiley
摘要:Abstract(#br)Persistently activated IL‐6/STAT3 pathway promotes acquired resistance to targeted therapy with epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) in non–small‐cell lung cancer (NSCLC) treatment. miR‐206 has been verified to be dys...
作者:Wei Wang , Shaowei Mo ...
来源:[J].Journal of Cellular and Molecular Medicine(IF 4.753), 2018, Vol.22 (10), pp.4935-4947Wiley
摘要:Abstract(#br)Currently, resistance to trastuzumab, a human epidermal growth factor receptor 2 (HER2) inhibitor, has become one major obstacle for improving the clinical outcome of patients with advanced HER2+ breast cancer. While cell behaviour can be modulated by...
作者:Wei Wang , Bin He ...
来源:[J].Journal of Cellular and Molecular Medicine(IF 4.753), 2019, Vol.23 (10), pp.6730-6743Wiley
摘要:Abstract(#br)Osteoclast overactivation‐induced imbalance in bone remodelling leads to pathological bone destruction, which is a characteristic of many osteolytic diseases such as rheumatoid arthritis, osteoporosis, periprosthetic osteolysis and periodontitis. Natural compoun...
作者:Wei Wang , Chuanzhen Chi ...
来源:[J].Journal of Cellular and Molecular Medicine(IF 4.753), 2019, Vol.23 (3), pp.2077-2082Wiley
摘要:Abstract(#br)Pleiotrophin (PTN) is involved in tumour progression, angiogenesis and metastasis. The purpose of this study was to investigate the expression level of PTN in the serum of patients with small cell lung cancer (SCLC) and to explore the clinical significance of PT...
作者:Wei Wang , Shuai Huang ...
来源:[J].Journal of Cellular and Molecular Medicine(IF 4.753), 2019, Vol.23 (10), pp.6846-6858Wiley
摘要:Abstract(#br)Pyruvate kinase M2 (PKM2), playing a central role in regulating aerobic glycolysis, was considered as a promising target for cancer therapy. However, its role in cancer metastasis is rarely known. Here, we found a tight relationship between PKM2 and breast cance...
作者:Wei Wang , Junqing Wu ...
来源:[J].Journal of Cellular and Molecular Medicine(IF 4.753), 2018, Vol.22 (12), pp.5955-5963Wiley
摘要:Abstract(#br)Accumulating evidence shows that tigecycline, a first‐in‐class glycylcycline, has potential antitumour properties. Here, we found that tigecycline dramatically inhibited the proliferation of multiple myeloma ( MM ) cell lines RPMI ‐8226, NCI ‐H929 and U266 ...
作者:... Ping Lv , Wei Wang , Yongyong Mu
来源:[J].Journal of Cellular and Molecular Medicine(IF 4.753), 2018, Vol.22 (10), pp.5062-5075Wiley
摘要:Abstract(#br)This study was designed to investigate whether ANRIL affected the aetiology of coronary artery disease ( CAD ) by acting on downstream miR‐181b and NF ‐κB signalling. Altogether 327 CAD patients diagnosed by angiography were included, and mice models of CAD...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×